FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, more specifically to peptide inducers of antitumor immunity; it can be used in medicine for the treatment or prevention of malignant tumor expressing stearoyl-coA-desaturase 1 (SCD1) protein. A composition is proposed, containing as an active ingredient effective amount of at least one polypeptide having immunity induction activity selected from polypeptides with SEQ ID NO: 3-36 binding to MHC molecule of the I class and polypeptides with SEQ ID NO: 37-45 binding to MHC molecule of the II class. A composition based on selected antigen-representing cell containing complex of MHC molecule and at least one of the specified polypeptides is proposed.
EFFECT: invention provides for higher activity in immunity induction against malignant tumor cells expressing SCD1 protein in comparison with full-size SD1 protein with SEQ ID NO: 2.
4 cl, 6 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| VACCINE COMPOSITION FOR MALIGNANT TUMOR | 2013 |
|
RU2721574C2 |
| NEIL3 PEPTIDES AND VACCINES COMPRISING THEM | 2010 |
|
RU2733985C2 |
| PEPTIDE OBTAINED FROM DEPDC1 AND VACCINE CONTAINING IT | 2016 |
|
RU2765574C2 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
| PEPTIDE, OBTAINED FROM MPHOSPH1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2731099C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
